ICCM News and Press, IceCure Medical Ltd. From 05/20/24

IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase PR Newswire CAESAREA, Israel , May 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or...

Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally PR Newswire Study published in the peer reviewed journal Breast Cancer ...

2024-04-17 08:21:19 ET Losers: Arrowroot Acquisition Corp ( AILE ) -34% . Hub Cyber Security Ltd ( HUBC ) -22% . Longeveron ( LGVN ) -18% announces exercise of warrants for $6.2 Million gross proceeds . Sage Therapeutics SAGE -19% after mi...

2024-04-15 10:06:29 ET DENVER, Colo., Apr 15, 2024 ( 247marketnews.com )- IceCure Medical Ltd. (NASDAQ: ICCM ) stated that it submitted final data to the U.S. Food and Drug Administration (“FDA”) requesting marketing authorization for ProSense, which received the FDA&#...

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer PR Newswire Data presentation ...

2024-04-03 13:20:27 ET IceCure Medical Ltd. (ICCM) Q4 2023 Earnings Conference Call April 03, 2024, 10:00 AM ET Company Participants Michael Polyviou - EVC Group, Investor Relations Eyal Shamir - Chief Executive Officer Shad Wood - VP of Sales, North American ...

2024-04-03 10:42:06 ET More on IceCure Medical FDA agrees to review IceCure request for De Novo classification Seeking Alpha’s Quant Rating on IceCure Medical Historical earnings data for IceCure Medical Financial information for IceCure Medical ...

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance PR Newswire Co...

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes PR Newswire Continuous innovation as a global leader in minimally invasive liquid-nitrogen based cryoablation systems CAESAREA, Israel , April 2, 2024 /PR...

IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 PR Newswire Overview of U.S. Commercial Strategy will be Discussed on Conference Ca...